Hua Jie, Shi Si, Liang Dingkong, Liang Chen, Meng Qingcai, Zhang Bo, Ni Quanxing, Xu Jin, Yu Xianjun
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China,
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China,
Onco Targets Ther. 2018 Aug 6;11:4591-4608. doi: 10.2147/OTT.S166405. eCollection 2018.
Pancreatic cancer remains one of the most lethal malignant diseases worldwide. The majority of patients present with advanced disease and, therefore, need palliative chemotherapy. Some chemotherapeutic regimens have been well established as first-line therapies and have been shown to increase survival; however, almost all patients with advanced pancreatic cancer will experience disease progression after first-line therapy. Nevertheless, many patients who retain good performance status after initial treatment remain good candidates for additional therapy. Historically, few studies have assessed second-line therapy, with most reports representing small phase II trials with variable findings; however, clinical research for second-line treatment has increased in the past decade, and several randomized controlled trials using different regimens have been published. The current literature shows varying results on treatment efficacy and tolerability. Thus, we reviewed the published data on the use of chemotherapy in the second-line setting for the treatment of advanced pancreatic cancer.
胰腺癌仍然是全球最致命的恶性疾病之一。大多数患者就诊时已处于疾病晚期，因此需要接受姑息化疗。一些化疗方案已被确立为一线治疗方案，并已显示可延长生存期；然而，几乎所有晚期胰腺癌患者在一线治疗后都会出现疾病进展。尽管如此，许多在初始治疗后仍保持良好身体状况的患者仍是接受额外治疗的合适人选。从历史上看，很少有研究评估二线治疗，大多数报告是小型II期试验，结果各异；然而，在过去十年中，二线治疗的临床研究有所增加，并且已经发表了几项使用不同方案的随机对照试验。目前的文献显示，在治疗效果和耐受性方面结果各异。因此，我们回顾了已发表的关于在二线治疗中使用化疗治疗晚期胰腺癌的数据。
